SCHEMBL15212914

SCHEMBL15212914

CC(C)C1(O)C(=O)Nc2cc(Nc3nc4c(-c5cnn(C)c5)nccn4n3)ccc21

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SYK P43405 1/20 1.00
EIF2AK4 Q9P2K8 1/20 1.00
JAK2 O60674 7/20 0.35
CDK2 P24941 8/20 0.35
CCNA2 P20248 1/20 0.35
TTK P33981 1/20 0.35
BTK Q06187 1/20 0.34
CCNE2 O96020 7/20 0.33
CCNE1 P24864 7/20 0.33
CCNB2 O95067 6/20 0.33
CDK1 P06493 6/20 0.33
CCNB1 P14635 6/20 0.33
CDK5 Q00535 6/20 0.33
CDK5R1 Q15078 6/20 0.33
CCNB3 Q8WWL7 6/20 0.33
CCNT1 O60563 6/20 0.33
CDK9 P50750 6/20 0.33
AXL P30530 1/20 0.33
JAK3 P52333 1/20 0.33
FLT3 P36888 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15210671 0.90 SYK (0.81) SYKEIF2AK4JAK2CDK2CCNA2
SCHEMBL15210757 0.88 SYK (0.78) SYKEIF2AK4JAK2CDK2CCNA2
SCHEMBL16407132 0.88 SYK (0.78) SYKEIF2AK4JAK2CDK2CCNA2
SCHEMBL15212554 0.85 SYK (0.75) SYKEIF2AK4JAK2CDK2CCNA2
SCHEMBL15210845 0.85 SYK (0.74) SYKEIF2AK4JAK2CDK2CCNA2
SCHEMBL16407157 0.85 SYK (0.74) SYKEIF2AK4JAK2CDK2CCNA2
SCHEMBL16407127 0.83 SYK (0.72) SYKEIF2AK4JAK2CDK2CCNA2
SCHEMBL15221230 0.83 SYK (0.71) SYKEIF2AK4JAK2CDK2CCNA2
SCHEMBL15212605 0.83 SYK (0.71) SYKEIF2AK4JAK2CDK2CCNA2
SCHEMBL15210729 0.82 SYK (0.70) SYKEIF2AK4JAK2CDK2CCNA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150025058-A1 8 - SUBSTITUTED 2 -AMINO - [1,2,4] TRIAZOLO [1, 5 -A] PYRAZINES AS SYK TRYROSINE KINASE INHIBITORS AND GCN2 SERIN KINASE INHIBITORS MERCK PATENT GMBH (DE) 2015-01-22 US claimed
EP-2817310-A1 8 - SUBSTITUTED 2 -AMINO - [1,2,4]TRIAZOLO [1, 5 -A]PYRAZINES AS SYK TRYROSINE KINASE INHIBITORS AND GCN2 SERIN KINASE INHIBITORS Merck Patent GmbH (DE) 2014-12-31 EP claimed
WO-2013124026-A1 8 - SUBSTITUTED 2 -AMINO - [1,2,4] TRIAZOLO [1, 5 -A] PYRAZINES AS SYK TRYROSINE KINASE INHIBITORS AND GCN2 SERIN KINASE INHIBITORS MERCK PATENT GMBH (DE) 2013-08-29 WO claimed
EP-2817310-B1 8-SUBSTITUTED 2-AMINO-[1,2,4]TRIAZOLO[1,5-A]PYRAZINES AS SYK TRYROSINE KINASE INHIBITORS AND GCN2 SERIN KINASE INHIBITORS MERCK PATENT GMBH (DE) 2018-03-21 EP disclosed
EP-2817310-B1 8-SUBSTITUTED 2-AMINO-[1,2,4]TRIAZOLO[1,5-A]PYRAZINES AS SYK TRYROSINE KINASE INHIBITORS AND GCN2 SERIN KINASE INHIBITORS MERCK PATENT GMBH (DE) 2018-03-21 EP disclosed
US-9120804-B2 8-substituted 2-amino-[1,2,4] triazolo [1, 5-A] pyrazines as Syk tryrosine kinase inhibitors and GCN2 serin kinase inhibitors MERCK PATENT GMBH (DE) 2015-09-01 US disclosed
US-9120804-B2 8-substituted 2-amino-[1,2,4] triazolo [1, 5-A] pyrazines as Syk tryrosine kinase inhibitors and GCN2 serin kinase inhibitors MERCK PATENT GMBH (DE) 2015-09-01 US disclosed
US-20150025058-A1 8 - SUBSTITUTED 2 -AMINO - [1,2,4] TRIAZOLO [1, 5 -A] PYRAZINES AS SYK TRYROSINE KINASE INHIBITORS AND GCN2 SERIN KINASE INHIBITORS MERCK PATENT GMBH (DE) 2015-01-22 US disclosed
US-20150025058-A1 8 - SUBSTITUTED 2 -AMINO - [1,2,4] TRIAZOLO [1, 5 -A] PYRAZINES AS SYK TRYROSINE KINASE INHIBITORS AND GCN2 SERIN KINASE INHIBITORS MERCK PATENT GMBH (DE) 2015-01-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150025058-A1 8 - SUBSTITUTED 2 -AMINO - [1,2,4] TRIAZOLO [1, 5 -A] PYRAZINES AS SYK TRYROSINE KINASE INHIBITORS AND GCN2 SERIN KINASE INHIBITORS SYK, EIF2AK4, BTK SYK 1/4885EIF2AK4 2/4885JAK2 29/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.